In 1980, the World Health Organization (WHO) officially declared that smallpox had been eradicated. In 1986, WHO's international Ad Hoc Committee on Orthopox Virus Infections unanimously recommended destruction of the two remaining official stocks of variola virus, one at the Centers for Disease Control and Prevention and the other at the VECTOR laboratory in Siberia. In June 1999, WHO decided to delay the destruction of these stocks. Informing that decision was Assessment of Future Scientific Needs for Variola Virus, which examines:
-- Whether the sequenced variola genome, vaccinia, and monkey pox virus are adequate for future research or whether the live variola virus itself is needed to assist in the development of antiviral therapies.
-- What further benefits, if any, would likely be gained through the use of variola in research and development efforts related to agent detection, diagnosis, prevention, and treatment.
-- What unique potential benefits, if any, the study of variola would have in increasing our fundamental understanding of the biology, host-agent interactions, pathogenesis, and immune mechanisms of viral diseases.
Table of Contents
|Part I. Introduction||5-6|
|Part II. Smallpox and Its Control||15-16|
|2 Variola Virus and Other Orthopoxviruses||17-24|
|3 Clinical Features of Smallpox||25-32|
|5 Variola Virus Stocks Following Eradication of Smallpox||37-44|
|Part III. Scientific Needs for Variola Virus||45-46|
|6 Development of Antiviral Agents||47-52|
|7 Development of Vaccines||53-58|
|8 Detection and Diagnosis||59-62|
|10 Understanding of the Biology of Variola Virus||69-72|
|11 Research on the Expressed Protein Products of Variola||73-76|
|Part IV. Findings||77-78|
|12 Summary and Conclusions||79-86|
|Appendix A Glossary||93-98|
|Appendix B Acronyms||99-100|
|Appendix C Committee and Staff Biographies||101-108|
Find relevant information like your own rough draft from among the thousands of reports available for free at NAP.edu. Copy and paste up to 8 pages of content—whether from your own draft or an outside article—and Reference Finder will recommend NAP publications related to your text.
View Reference Finder
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, please click here to view more information.
Loading stats for Assessment of Future Scientific Needs for Live Variola Virus...